Investor Relations

Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna is leveraging over a decade of extensive research to advance a pipeline of differentiated small molecules engineered to stabilize CFTR’s nucleotide-binding domain 1 (NBD1), where the most common CF genetic mutation F508del resides. The company is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR activity, which Sionna believes is central to unlocking dramatic improvements in clinical outcomes and quality of life for CF patients.